Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
13.91
+0.46 (3.45%)
Oct 8, 2025, 9:30 AM EDT - Market open
Daxor Revenue
Daxor had revenue of $18.35K in the half year ending June 30, 2025, a decrease of -77.34%. This brings the company's revenue in the last twelve months to $66.31K, down -57.00% year-over-year. In the year 2024, Daxor had annual revenue of $119.71K, down -26.75%.
Revenue (ttm)
$66.31K
Revenue Growth
-57.00%
P/S Ratio
1,010.74
Revenue / Employee
$1,473
Employees
45
Market Cap
69.33M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 119.71K | -43.71K | -26.75% |
Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
Dec 31, 2020 | 264.44K | -115.70K | -30.44% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
DXR News
- 8 days ago - Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA - GlobeNewsWire
- 15 days ago - Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting - GlobeNewsWire
- 4 weeks ago - Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care - GlobeNewsWire
- 5 weeks ago - Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 weeks ago - Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter - GlobeNewsWire
- 2 months ago - Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System - GlobeNewsWire
- 2 months ago - Daxor's Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions - GlobeNewsWire
- 5 months ago - Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal - GlobeNewsWire